Clinical Trial Update: DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial of DZD8586 in relapsed or refractory B-cell non-Hodgkin lymphoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• DZD8586

Snippet

Sponsor: Dizal Pharmaceuticals | Conditions: Lymphoma, Non-Hodgkin | Phase 1 | Status: RECRUITING